|1.||Boon, L: 1 article (08/2000)|
|2.||Lemoli, R M: 1 article (08/2000)|
|3.||Tazzari, P L: 1 article (08/2000)|
|4.||Polito, L: 1 article (08/2000)|
|5.||Bolognesi, A: 1 article (08/2000)|
|6.||Fogli, M: 1 article (08/2000)|
|7.||Stirpe, F: 1 article (08/2000)|
|8.||Lubelli, C: 1 article (08/2000)|
|9.||de Boer, M: 1 article (08/2000)|
|1.||Hodgkin Disease (Hodgkin's Disease)
08/01/2000 - "Present results suggest that immunotoxins targeting type 1 ribosome-inactivating proteins to these antigens could be considered and further studied for the therapy of Hodgkin's disease or other CD80/CD86-expressing tumours."
10/01/1995 - "In this study, we compared the ability of different bispecific monoclonal antibodies (BsmAb) and immunotoxins to deliver the type 1 ribosome-inactivating proteins (RIP) saporin and gelonin through the CD25 or CD30 target molecules to Hodgkin's lymphoma cells. "
02/08/1996 - "Immunotoxins were prepared by linking the type 1 ribosome-inactivating proteins (RIP) momordin I, pokeweed antiviral protein from seeds (PAP-S) and saporin-S6 to the 48-127 monoclonal antibody (MAb) recognising a glycoprotein (gp54) expressed on all human bladder tumours tested and on human bladder carcinoma cell lines, in particular on the T24 cell line. "
|4.||Gelonium multiflorum GEL protein
|8.||pokeweed antiviral protein